Etoricoxib
- Generic Name
- Etoricoxib
- Drug Type
- Small Molecule
- Chemical Formula
- C18H15ClN2O2S
- CAS Number
- 202409-33-4
- Unique Ingredient Identifier
- WRX4NFY03R
- Background
Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.
- Indication
For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout.
- Associated Conditions
- Ankylosing Spondylitis (AS), Gout, Osteoarthritis (OA), Rheumatoid Arthritis, Moderate Pain
Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis
- Conditions
- Gout ArthritisGout Attack
- Interventions
- Drug: Etoricoxib + Betamethasone fixed dose
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 72
- Registration Number
- NCT06863701
- Locations
- 🇲🇽
Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico
Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm
- Conditions
- Acute Low-back PainMuscle Spasm; Back Pain
- Interventions
- Drug: Etoricoxib + Tizanidine fixed dose
- First Posted Date
- 2025-03-07
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 136
- Registration Number
- NCT06863662
- Locations
- 🇲🇽
Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico
Efficacy and Safety of Etoricoxib/Cyanocobalamin Versus Etoricoxib for Acute Low Back Pain
- Conditions
- Acute Low-back Pain
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 190
- Registration Number
- NCT06517823
- Locations
- 🇲🇽
Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Muhammad Ilyas
- Target Recruit Count
- 140
- Registration Number
- NCT06401499
Immediate Analgesic Effects of Cheek Acupuncture for Acute Gouty Arthritis
- Conditions
- AcupunctureAcute PainAcute Gout Arthritis
- Interventions
- Other: cheek acupuncture
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Guangdong Provincial Hospital of Traditional Chinese Medicine
- Target Recruit Count
- 76
- Registration Number
- NCT06001112
- Locations
- 🇨🇳
Yupinglin Lin, GuangZhou, Guangdong, China
Effect of Preemptive Etoricoxib and Dexamethasone on Wound Healing and Clinical Parameters After Third Molar Surgery
- Conditions
- Surgical WoundPost Operative Pain
- Interventions
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2023-03-30
- Lead Sponsor
- University of Belgrade
- Target Recruit Count
- 90
- Registration Number
- NCT05791721
- Locations
- 🇷🇸
School of Dental medicine, University of Belgrade, Belgrade, Serbia
Fixed-dose Combination of Etoricoxib + Cyclobenzaprine for Pain Relief After Third Molar Extraction in Brazil
- Conditions
- Third Molar Extraction
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Eurofarma Laboratorios S.A.
- Registration Number
- NCT05683574
- Locations
- 🇧🇷
Eurofarma Laboratorios S.A, São Paulo, SP, Brazil
Bioequivalence Study of Etoricoxib in Healthy Adult Subjects Under Fasting Condition
- Conditions
- Healthy Subjects
- Interventions
- Drug: Arcoxia 90 mg film coated tablet
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Future University in Egypt
- Target Recruit Count
- 30
- Registration Number
- NCT05532280
- Locations
- 🇪🇬
Future Research Center (FRC), Cairo, Egypt
Comparative Bioavailability Study Between Etoricoxib and Tramadol, Administered Individually or in Combination
- Conditions
- Healthy
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 42
- Registration Number
- NCT05533073
- Locations
- 🇲🇽
Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico
Biomarkers for Prediction of Analgesic Efficacy in Knee OA.
- Conditions
- Knee, Osteoarthritis (OA)Biomarkers for Prediction of OA Treatment Efficacy
- Interventions
- First Posted Date
- 2022-02-25
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Rambam Health Care Campus
- Target Recruit Count
- 17
- Registration Number
- NCT05256342
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.